Aim: To compare the 2-year survival rates of polypropylene and silicone Ahmed glaucoma valves (AGVs) implanted during the first 2 years of life.
Methods: Retrospective analysis of polypropylene and silicone AGV implantation during the first 2 years of life in children with 2 years’ postoperative follow-up. Patients with prior aqueous drainage device implantation were excluded.
Results: Forty-two eyes of 36 children were reviewed. Thirty-one eyes received a polypropylene AGV (six S1, 25 S2), and 11 eyes received a silicone AGV (11 FP7). The average survival time (maintenance of intraocular pressure ⩽22 mm Hg with (or without) medications and without significant complications) was significantly longer (p = 0.001 by the logrank test) for the silicone group (23.36 months, standard error (SE) 1.64, 95% confidence interval (CI) 20.16 to 24.00 months) than for the polypropylene group (19.10 months, SE 1.53, 95% CI 16.1 to 22.12 months). Cumulative probabilities of survival at 2 years by Kaplan to Meier analysis were 90.9% (SE 8.7, 95% CI 70 to 100%) and 54.8% (SE 8.9, 95% CI 23 to 87%), respectively (p = 0.001 by the logrank test). All eyes implanted with silicone AGVs had the diagnosis of congenital glaucoma, which was independently associated with 2-year survival.
Conclusions: Two years after surgery, silicone AGVs survived longer than polypropylene AGVs. However, all eyes that received silicone AGVs in our cohort had congenital glaucoma, which had a better survival than other paediatric glaucoma diagnoses. A study of silicone AGV implantation in other paediatric glaucoma diagnoses is needed to determine whether or not silicone AGVs independently have a better survival after implantation in the first 2 years of life.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Competing interests: None.
Ethics approval: Ethics approval was provided by King Khaled Eye Specialist Hospital.